EA200200847A1 - Производные пиперазина и пиперидина для лечения и профилактики поврежденных нейронов - Google Patents
Производные пиперазина и пиперидина для лечения и профилактики поврежденных нейроновInfo
- Publication number
- EA200200847A1 EA200200847A1 EA200200847A EA200200847A EA200200847A1 EA 200200847 A1 EA200200847 A1 EA 200200847A1 EA 200200847 A EA200200847 A EA 200200847A EA 200200847 A EA200200847 A EA 200200847A EA 200200847 A1 EA200200847 A1 EA 200200847A1
- Authority
- EA
- Eurasian Patent Office
- Prior art keywords
- piperazine
- piperidine
- derivatives
- prevention
- treatment
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/04—Drugs for skeletal disorders for non-specific disorders of the connective tissue
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D205/00—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom
- C07D205/02—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom not condensed with other rings
- C07D205/04—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D207/04—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D207/10—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D207/16—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
- C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
- C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D211/60—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
- C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D211/60—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
- C07D211/62—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals attached in position 4
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
- C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
- C07D277/04—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
- C07D277/06—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having no double bonds between ring members or between ring members and non-ring members with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/08—Bridged systems
Landscapes
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- General Chemical & Material Sciences (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Psychology (AREA)
- Pain & Pain Management (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Rheumatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Hydrogenated Pyridines (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Thiazole And Isothizaole Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Pyrrole Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Indole Compounds (AREA)
Abstract
Настоящее изобретение относится к производным пиперазина и пиперидина, которые особенно пригодны для лечения или предупреждения повреждения нейронов, особенно повреждения, связанного с неврологическими заболеваниями. Данные соединения также пригодны для стимуляции роста нервной ткани. Изобретение также представляет композиции, включающие соединения по настоящему изобретению, и способы применения данных композиций для лечения или предотвращения повреждения нейронов или для стимуляции роста нервной ткани.Отчет о международном поиске был опубликован 2002.04.25.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US18194400P | 2000-02-11 | 2000-02-11 | |
US24733000P | 2000-11-10 | 2000-11-10 | |
PCT/US2001/004210 WO2001058891A2 (en) | 2000-02-11 | 2001-02-09 | Piperazine and piperidine derivatives for treatment or prevention of neuronal damage |
Publications (1)
Publication Number | Publication Date |
---|---|
EA200200847A1 true EA200200847A1 (ru) | 2003-02-27 |
Family
ID=26877657
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EA200200847A EA200200847A1 (ru) | 2000-02-11 | 2001-02-09 | Производные пиперазина и пиперидина для лечения и профилактики поврежденных нейронов |
Country Status (23)
Country | Link |
---|---|
EP (1) | EP1257544B1 (ru) |
JP (1) | JP2003522767A (ru) |
KR (1) | KR20020073586A (ru) |
CN (1) | CN1210274C (ru) |
AP (1) | AP2002002596A0 (ru) |
AU (1) | AU4146401A (ru) |
BR (1) | BR0108175A (ru) |
CA (1) | CA2398822A1 (ru) |
CO (1) | CO5261503A1 (ru) |
CZ (1) | CZ20022720A3 (ru) |
EA (1) | EA200200847A1 (ru) |
EE (1) | EE200200442A (ru) |
HR (1) | HRP20020737A2 (ru) |
HU (1) | HUP0301391A3 (ru) |
IL (1) | IL150849A0 (ru) |
IS (1) | IS6477A (ru) |
MX (1) | MXPA02007790A (ru) |
NO (1) | NO20023787L (ru) |
NZ (1) | NZ520638A (ru) |
PE (1) | PE20011081A1 (ru) |
PL (1) | PL357177A1 (ru) |
SK (1) | SK11452002A3 (ru) |
WO (1) | WO2001058891A2 (ru) |
Families Citing this family (30)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6809093B2 (en) | 2000-10-17 | 2004-10-26 | H. Lee Moffitt Cancer & Research Institute, Inc. | 2-substituted heterocyclic compounds |
HUP0303376A3 (en) | 2001-02-28 | 2007-08-28 | Merck & Co Inc | Acylated piperidine derivatives as melanocortin-4 receptor agonists, and pharmaceutical compositions containing them and use thereof |
ATE341327T1 (de) | 2001-02-28 | 2006-10-15 | Merck & Co Inc | Acylierte piperidin-derivate als melanocortin-4- rezeptor-agonisten |
CA2439119A1 (en) | 2001-02-28 | 2002-09-06 | Merck & Co., Inc. | Acylated piperidine derivatives as melanocortin-4 receptor agonists |
DE60229393D1 (de) | 2001-07-18 | 2008-11-27 | Merck & Co Inc | Überbrückte piperidinderivate als melanocortin-rezeptor-agonisten |
JP4320252B2 (ja) * | 2001-09-06 | 2009-08-26 | シェーリング コーポレイション | アンドロゲン依存性疾患の処置のための1β−ヒドロキシステロイドデヒドロゲナーゼ3型インヒビター |
JP2005511560A (ja) * | 2001-11-01 | 2005-04-28 | バーテックス ファーマシューティカルズ インコーポレイテッド | コレステロール生合成経路の変調 |
US7414057B2 (en) | 2002-09-11 | 2008-08-19 | Merck & Co., Inc. | Piperazine urea derivatives as melanocortin-4 receptor agonists |
DE60326742D1 (de) * | 2002-10-03 | 2009-04-30 | Vertex Pharma | Piperazin und piperadin-derivate für die behandlung von neurologischen krankheiten |
AR043434A1 (es) | 2003-03-03 | 2005-07-27 | Merck & Co Inc | Derivados de piperizacina acilados como agonistas del receptor de melanocortina-4. composiciones farmaceuticas y usos |
CN101880277A (zh) | 2003-04-24 | 2010-11-10 | 因塞特公司 | 作为金属蛋白酶抑制剂的氮杂螺烷衍生物 |
EP1524265A1 (en) * | 2003-10-15 | 2005-04-20 | Newron Pharmaceuticals S.p.A. | Prolinamide derivatives as sodium and/or calcium channel blockers or selective MAO-B inhibitors |
DE602005018779D1 (de) | 2004-07-19 | 2010-02-25 | Merck & Co Inc | Acylierte piperidinderivative als melanocortin-4-rezeptoragonisten |
GB0508319D0 (en) | 2005-04-25 | 2005-06-01 | Novartis Ag | Organic compounds |
KR20080021082A (ko) | 2005-06-20 | 2008-03-06 | 쉐링 코포레이션 | 히스타민 h3 길항제로서 유용한 피페리딘 유도체 |
WO2007002057A1 (en) * | 2005-06-20 | 2007-01-04 | Schering Corporation | Carbon-linked substituted piperidines and derivatives thereof useful as histamine h3 antagonists |
GB0514018D0 (en) * | 2005-07-07 | 2005-08-17 | Ionix Pharmaceuticals Ltd | Chemical compounds |
EP1988920A1 (en) | 2006-02-02 | 2008-11-12 | Rinat Neuroscience Corp. | Methods for treating obesity by administering a trkb antagonist |
AU2007311591B2 (en) | 2006-10-18 | 2010-10-07 | Pfizer Products Inc. | Biaryl ether urea compounds |
CA2743489A1 (en) | 2008-11-17 | 2010-05-20 | Merck Sharp & Dohme Corp. | Substituted bicyclic amines for the treatment of diabetes |
WO2011011506A1 (en) | 2009-07-23 | 2011-01-27 | Schering Corporation | Spirocyclic oxazepine compounds as stearoyl-coenzyme a delta-9 desaturase inhibitors |
WO2011011508A1 (en) | 2009-07-23 | 2011-01-27 | Schering Corporation | Benzo-fused oxazepine compounds as stearoyl-coenzyme a delta-9 desaturase inhibitors |
US8785634B2 (en) | 2010-04-26 | 2014-07-22 | Merck Sharp & Dohme Corp | Spiropiperidine prolylcarboxypeptidase inhibitors |
EP2568812B1 (en) | 2010-05-11 | 2016-10-26 | Merck Sharp & Dohme Corp. | Novel prolylcarboxypeptidase inhibitors |
US9006268B2 (en) | 2010-06-11 | 2015-04-14 | Merck Sharp & Dohme Corp. | Prolylcarboxypeptidase inhibitors |
US8729263B2 (en) | 2012-08-13 | 2014-05-20 | Novartis Ag | 1,4-disubstituted pyridazine analogs there of and methods for treating SMN-deficiency-related conditions |
AU2014296255B2 (en) * | 2013-07-31 | 2017-08-03 | Novartis Ag | 1,4-disubstituted pyridazine derivatives and their use for treating SMN-deficiency-related conditions |
JP6985179B2 (ja) * | 2018-02-27 | 2021-12-22 | 田辺三菱製薬株式会社 | プロリンアミド化合物の製造方法 |
AU2020282757A1 (en) | 2019-05-31 | 2021-12-23 | Ikena Oncology, Inc. | TEAD inhibitors and uses thereof |
MX2021014441A (es) | 2019-05-31 | 2022-01-06 | Ikena Oncology Inc | Inhibidores del dominio asociado mejorador de la transcripcion (tead) y usos de los mismos. |
Family Cites Families (12)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
BE791501A (fr) * | 1971-11-19 | 1973-05-17 | Albert Ag Chem Werke | Diamines cycliques n,n'-disubstituees et leur procede de preparation |
US3862937A (en) * | 1972-02-23 | 1975-01-28 | Univ Mississippi | 6-Phenethyl-3-piperidinecarboxamides |
FR2597100A1 (fr) * | 1986-01-21 | 1987-10-16 | Nippon Shinyaku Co Ltd | Derives du pyroglutamide |
US4745123A (en) * | 1986-02-18 | 1988-05-17 | Warner-Lambert Company | Substituted tetrahydro-3-pyridine-carboxylic acid, ester, and amide cholinergic agents |
US5232923A (en) * | 1988-03-18 | 1993-08-03 | Mitsui Toatsu Chemicals, Incorporated | Catechol derivatives and pharmaceutical preparations containing same |
NZ228329A (en) * | 1988-03-18 | 1991-12-23 | Mitsui Toatsu Chemicals | Catechol derivatives and pharmaceutical compositions thereof |
US5290793A (en) * | 1989-09-12 | 1994-03-01 | Mitsui Toatsu Chemicals, Incorporated | Dihydrocaffeic acid derivatives and pharmaceutical preparation containing same |
FR2705095B1 (fr) | 1993-05-12 | 1995-06-23 | Adir | Nouveaux indoles substitués, leur procédé de préparation et les compositions pharmaceutiques qui les contiennent. |
US5614547A (en) | 1995-06-07 | 1997-03-25 | Guilford Pharmaceuticals Inc. | Small molecule inhibitors of rotamase enzyme |
US5811434A (en) * | 1996-11-13 | 1998-09-22 | Vertex Pharmacueticals Incorporated | Methods and compositions for stimulating neurite growth |
PA8442401A1 (es) * | 1996-12-09 | 2000-05-24 | Guilford Pharm Inc | Inhibidores polipropilos de ciclofilina |
JPH11106375A (ja) * | 1997-08-18 | 1999-04-20 | Pfizer Pharmaceut Inc | ブラジキニンアンタゴニストとしての光学的に活性な1,4−ジヒドロピリジン化合物 |
-
2001
- 2001-02-09 EP EP01912714A patent/EP1257544B1/en not_active Expired - Lifetime
- 2001-02-09 CN CNB018048021A patent/CN1210274C/zh not_active Expired - Fee Related
- 2001-02-09 BR BR0108175-6A patent/BR0108175A/pt not_active IP Right Cessation
- 2001-02-09 EA EA200200847A patent/EA200200847A1/ru unknown
- 2001-02-09 SK SK1145-2002A patent/SK11452002A3/sk not_active Application Discontinuation
- 2001-02-09 MX MXPA02007790A patent/MXPA02007790A/es unknown
- 2001-02-09 AP APAP/P/2002/002596A patent/AP2002002596A0/en unknown
- 2001-02-09 CO CO01009891A patent/CO5261503A1/es unknown
- 2001-02-09 WO PCT/US2001/004210 patent/WO2001058891A2/en active IP Right Grant
- 2001-02-09 PL PL01357177A patent/PL357177A1/xx not_active Application Discontinuation
- 2001-02-09 PE PE2001000144A patent/PE20011081A1/es not_active Application Discontinuation
- 2001-02-09 EE EEP200200442A patent/EE200200442A/xx unknown
- 2001-02-09 KR KR1020027010367A patent/KR20020073586A/ko not_active Application Discontinuation
- 2001-02-09 CZ CZ20022720A patent/CZ20022720A3/cs unknown
- 2001-02-09 NZ NZ520638A patent/NZ520638A/en unknown
- 2001-02-09 CA CA002398822A patent/CA2398822A1/en not_active Abandoned
- 2001-02-09 IL IL15084901A patent/IL150849A0/xx unknown
- 2001-02-09 JP JP2001558441A patent/JP2003522767A/ja active Pending
- 2001-02-09 AU AU41464/01A patent/AU4146401A/en not_active Abandoned
- 2001-02-09 HU HU0301391A patent/HUP0301391A3/hu unknown
-
2002
- 2002-07-19 IS IS6477A patent/IS6477A/is unknown
- 2002-08-09 NO NO20023787A patent/NO20023787L/no unknown
- 2002-09-09 HR HR20020737A patent/HRP20020737A2/hr not_active Application Discontinuation
Also Published As
Publication number | Publication date |
---|---|
EP1257544A2 (en) | 2002-11-20 |
BR0108175A (pt) | 2003-01-28 |
WO2001058891A3 (en) | 2002-04-25 |
CN1404477A (zh) | 2003-03-19 |
HRP20020737A2 (en) | 2005-10-31 |
NZ520638A (en) | 2004-05-28 |
HUP0301391A3 (en) | 2010-03-29 |
CN1210274C (zh) | 2005-07-13 |
KR20020073586A (ko) | 2002-09-27 |
WO2001058891A2 (en) | 2001-08-16 |
SK11452002A3 (sk) | 2003-03-04 |
PL357177A1 (en) | 2004-07-26 |
EP1257544B1 (en) | 2012-07-25 |
AU4146401A (en) | 2001-08-20 |
MXPA02007790A (es) | 2002-10-17 |
EE200200442A (et) | 2003-12-15 |
NO20023787L (no) | 2002-10-11 |
AP2002002596A0 (en) | 2002-09-30 |
IS6477A (is) | 2002-07-19 |
JP2003522767A (ja) | 2003-07-29 |
HUP0301391A2 (hu) | 2003-08-28 |
NO20023787D0 (no) | 2002-08-09 |
IL150849A0 (en) | 2003-02-12 |
CO5261503A1 (es) | 2003-03-31 |
CZ20022720A3 (cs) | 2002-11-13 |
CA2398822A1 (en) | 2001-08-16 |
PE20011081A1 (es) | 2001-10-22 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EA200200847A1 (ru) | Производные пиперазина и пиперидина для лечения и профилактики поврежденных нейронов | |
ATE362363T1 (de) | Verwendung von tnf-alpha inhibitoren zur behandlung von nervenwurzelschäden | |
NO20052153L (no) | Piperazin- og piperidinderivater for behandling av nevrologiske sykdommer. | |
DE60027431D1 (de) | Verwendung von p38 MAPK Inhibitoren in der Behandlung von Augenkrankheiten | |
ATE492279T1 (de) | Bupropinmetaboliten zur behandlung von dementia und anderen zerebrovasckulären erkrankungen | |
ATE386544T1 (de) | Photodynamische therapie zur behandlung von haarausfall | |
EP1474158A4 (en) | PREVENTING AND TREATING OXIDATIVE STRESS RELATED DISORDERS USING GLUTATHIONE AND PHASE II DETOXIFICATION ENZYMES | |
DE60029799D1 (de) | Verbindungen, verfahren und pharmazeutische zubereitungen zur behandlung von zellschäden wie zum beispiel schäden an nerven- oder kerzgefässgewebe | |
PL348715A1 (en) | Carboxylic acids and carboxylic acid isosteres of n−heterocyclic compounds | |
ATE218854T1 (de) | Behandlung von herzrythmusstörungen durch hemmung einer multifunktionalen calcium/calmodulin- abhängigen protein kinase | |
EA200001247A1 (ru) | N-связанные сульфонамиды n-гетероциклических карбоновых кислот или изостеры карбоновых кислот | |
ATE238792T1 (de) | Verwendung von makroliden zur behandlung von glaukom | |
DE60014136D1 (de) | Sapogenin derivate zur behandlung von kognitiven störungen | |
ATE260653T1 (de) | Verwendung von naaladase inhibitoren zur behandlung von angstzuständen und gedächtnisstörungen | |
EA200500934A1 (ru) | Соединения, модулирующие активность киназного белка множественных линий, и способы лечения нейродегенеративных и воспалительных заболеваний | |
ATE332688T1 (de) | Verwendung von carbinolen zur behandlung von neuropathischer funktionsstörung | |
ATE281841T1 (de) | Verfahren zur herstellung von mikania extrakten enthaltend mikanolide und dihydromikanolide und verwendung in der behandlung proliferativer erkrankungen | |
DE59907195D1 (de) | Verfahren zur behandlung von erkrankungen oder störungen des innenohrs | |
DE69912304D1 (de) | Verwendung von staurosporine derivaten zur behandlung von okularen neovaskularen erkrankungen | |
DE69822626T8 (de) | Verwendung eines nitroxids oder seiner prodrugs zur prophylaktischen und therapeutischen behandlung von krebs | |
ATE302011T1 (de) | PONAZURIL ZUR BEHANDLUNG VON DURCH COCCIDIA NEUROLOGISCHEN UND ßABORTIGENICß VERURSACHTEN ERKRANKUNGEN | |
ATE380551T1 (de) | Verwendung von brimonidine zur behandlung von dementia und morbus parkinson | |
ATE482217T1 (de) | Dithiolopyrrolon-derivate zur behandlung von proliferativen störungen | |
ATE350034T1 (de) | Verwendung von epothilone zur behandlung hyperparathyreoidismus | |
ATE361079T1 (de) | Verwendung von pyrimidinnukleotiden zur behandlung von schaedigungen des peripheren nervensystems |